Noviello S, Ianniello F, Esposito S
Clinica Malattie Infettive, Seconda Universita' di Napoli, Via Cotugno 1, 80135 Napoli, Italy.
J Antimicrob Chemother. 2001 Aug;48(2):283-6. doi: 10.1093/jac/48.2.283.
Gram-positive cocci are a major cause of nosocomial bacteraemias and are often resistant to most antibiotics. The emergence of enterococci with reduced susceptibility to vancomycin has created an urgent need for novel antibiotics to combat infections associated with these bacteria. In this study the in vitro activity of LY333328 (oritavancin), a semi-synthetic glycopeptide, was evaluated. LY333328 was effective against all strains of staphylococci, streptococci and enterococci tested. A combination of LY333328 and ciprofloxacin was additive for 50% of Enterococcus faecium strains resistant to both vancomycin and ciprofloxacin, and for 100% of vancomycin-susceptible and either ciprofloxacin-susceptible or -resistant strains.
革兰氏阳性球菌是医院获得性菌血症的主要病因，且常常对大多数抗生素耐药。对万古霉素敏感性降低的肠球菌的出现，迫切需要新型抗生素来对抗与这些细菌相关的感染。在本研究中，评估了半合成糖肽LY333328（奥利万星）的体外活性。LY333328对所有测试的葡萄球菌、链球菌和肠球菌菌株均有效。LY333328与环丙沙星联合使用时，对50%既耐万古霉素又耐环丙沙星的粪肠球菌菌株，以及对100%万古霉素敏感且对环丙沙星敏感或耐药的菌株具有相加作用。
